<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Clinically Important Drug Interactions with Repaglinide 
			</caption>
<colgroup>
<col width="17.3%"></col>
<col width="82.7%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Gemfibrozil</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Gemfibrozil significantly increased repaglinide exposures by 8.1 fold <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Do not administer repaglinide to patients receiving gemfibrozil <content stylecode="italics">[see <linkhtml href="#Section_4">Contraindications (4)</linkhtml>]</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Clopidogrel</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Clopidogrel increased repaglinide exposures by 3.9 to 5.1 fold <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Avoid concomitant use of repaglinide with clopidogrel. If concomitant use can not be avoided, initiate repaglinide at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg <content stylecode="italics">[see <linkhtml href="#Section_2.3">DOSAGE AND ADMINISTRATION (2.3)</linkhtml>]</content>. Increased frequency of glucose monitoring may be required during concomitant use.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Cyclosporine</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Cyclosporine increased low dose repaglinide exposures by 2.5 fold <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Daily maximum repaglinide dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when repaglinide is co-administered with cyclosporine.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> CYP2C8 and CYP3A4 Inhibitors</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Repaglinide dose reductions and increased frequency of glucose monitoring may be required when co­-administered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin). Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> CYP2C8 and CYP3A4 Inducers</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Repaglinide dose increases and increased frequency of glucose monitoring may be required when co-­administered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Drugs That May Increase the Risk of Hypoglycemia</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Repaglinide dose reductions and increased frequency of glucose monitoring may be required when co-­administered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="justify" colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Drugs That May Decrease the Blood Glucose Lowering Effect of Repaglinide</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Repaglinide dose increases and increased frequency of glucose monitoring may be required when co-­administered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Drugs That May Blunt Signs and Symptoms of Hypoglycemia</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Increased frequency of glucose monitoring may be required when repaglinide is co-administered with these drugs.<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Lrule Rrule" valign="middle">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">beta-blockers, clonidine, guanethidine, and reserpine<br/>
</td>
</tr>
</tbody>
</table>